Piramal Pharma Ltd – 15 Numbers That Will Make You Question Who’s Running the Show
1. At a Glance
Piramal Pharma Ltd is the pharma equivalent of a Bollywood star kid — born with pedigree, has the stage, but somehow keeps tripping on its own shoelaces. A ₹24,000+ Cr market cap giant that operates across CDMO, hospital generics, and OTC consumer brands. Yet with a P/E of 282, margins thinner than hostel chai, and ROE barely scratching 1%, one wonders — is this a pharma company or a charitable trust with global ambitions?
2. Introduction
Back in 1988, Piramal Pharma barged into pharma by buying Nicholas Labs, then went on an M&A spree like a kid in a candy shop. In 2010, it sold its domestic formulations business to Abbott for a juicy $3.7 billion, and diagnostics to SRL — essentially cashing out at the peak. Since then, it has been trying to reinvent itself through CDMO, complex hospital generics, and consumer healthcare.
Today, Piramal is a global player with 15 manufacturing sites spread across India, North America, and Europe, serving 100+ countries. CDMO is its bread and butter (58% of revenues), while complex hospital generics (30%) and consumer healthcare (12%) provide seasoning. It has ambitions to be a $2 billion pharma-health-wellness giant by FY30.
The reality? Working capital cycles stretching like chewing gum, interest coverage that barely covers chai, and a stock price that makes investors nostalgic about their FDs. So, is this a global pharma player or just a collection of half-cooked experiments with celebrity brand endorsements? Let’s put on our sarcastic auditor hat.
3. Business Model – WTF Do They Even Do?
Piramal Pharma earns money from three buckets:
CDMO (Contract Development & Manufacturing Operations) – The “rented lab coat” business. With 500+ customers, Piramal manufactures for others — drugs still on patent, generics, and discovery molecules. 84% of CDMO revenue comes from regulated markets like US, Europe, and Japan. Top 3 in India, 13th globally. Yet, margins are not exactly Divi’s Labs-level.
Complex Hospital Generics (CHG) – Think inhalation anesthesia, intrathecal therapy, pain management injections — basically stuff hospitals can’t afford to mess up. Piramal is the 4th largest IA player globally, supplying to 6000+ customers. But the business is tricky — approvals, compliance, and competition from larger global players squeeze pricing power.
India Consumer Healthcare (ICH) – The glamour business with brands like Lacto Calamine, Polycrol, Little’s, Tetmosol. Endorsed by Kareena Kapoor, Ajay Devgan, Amyra Dastur — because nothing screams medical science like celebrity ads. Sales grew from ₹100 Cr in 2008 to ₹1,000 Cr+ in FY24. Self-funded, asset-light, and promotion-heavy (~13% of sales blown on marketing).
So yes, Piramal is diversified. But as every MBA professor says — diversification without execution is just diworsification.
4. Financials Overview
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹1,934 Cr
₹1,951 Cr
₹2,754 Cr
-0.9%
-29.8%
EBITDA
₹107 Cr
₹204 Cr
₹561 Cr
-47.5%
-80.9%
PAT
-₹82 Cr
-₹89 Cr
₹154 Cr
7.9%
-153%
EPS (₹)
-0.61
-0.67
1.16
–
–
Commentary: Imagine running a ₹24,000 Cr company and still posting negative PAT in June’25. EBITDA crashed 80% QoQ — this isn’t cyclicality, it’s comedy. EPS oscillates between negative and barely positive like a student’s mood during CA exams. P/E of 282? Honestly, “P/E not meaningful” should be tattooed on this balance sheet.
5. Valuation – Fair Value Range Only
Three methods applied:
P/E Method: EPS (TTM) = ₹0.74 Industry P/E = 32 Fair Value = 0.74 × 32 = ₹24 (lol).
EV/EBITDA Method: EV = ₹28,732 Cr EBITDA (TTM) = ₹1,347 Cr EV/EBITDA = 21.3× vs industry avg ~15×. If repriced to 15× → EV = ₹20,205 Cr → Equity Value ≈ ₹15,350 Cr → Per Share ≈ ₹115.
DCF Method (optimistic): Assume revenue grows 10% CAGR for 5 years, OPM stabilises at 18%, WACC = 10%, terminal growth 4%. Fair Value ≈ ₹130–₹160.
Range: ₹115 – ₹160 per share.
⚠️ Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Fire at a third-party warehouse (Aug’25) caused ₹45 Cr inventory loss. Insurance claim underway. Great — pharma meets pyjama party.
Multi-million-dollar expansion in Sellersville, US for oral solid dosage (OSD) suite for NewAmsterdam Pharma. Jobs created, costs also
